<?xml version="1.0" encoding="UTF-8"?>
<references>
<reference>
  <a1>Peñalver, FJ</a1>
  <a2>Marquez, JA</a2>
  <a2>Duran, S</a2>
  <a2>Giraldo, P</a2>
  <a2>Martin, A</a2>
  <a2>Montalban, C</a2>
  <a2>Sancho, JM</a2>
  <a2>Ramirez, MJ</a2>
  <a2>Terol, MJ</a2>
  <a2>Capote, FJ</a2>
  <a2>Gutierrez, A</a2>
  <a2>Sanchez, B</a2>
  <a2>Lopez, A</a2>
  <a2>Salar, A</a2>
  <a2>Rodriguez-Caravaca, G</a2>
  <a2>Canales, M</a2>
  <a2>Caballero, MD</a2>
  <a2>Lopez, JLB</a2>
  <a2>Carbonell, F</a2>
  <a2>Bordas, SF</a2>
  <a2>Lopez, PF</a2>
  <a2>Persona, EP</a2>
  <a2>Guillermo, AL</a2>
  <a2>Martin, RH</a2>
  <a2>Mayans, JR</a2>
  <a2>Palomera, L</a2>
  <a2>Ceballos, EP</a2>
  <a2>Hernandez, JAQ</a2>
  <a2>Grau, RR</a2>
  <a2>de la Cruz, F</a2>
  <a2>Salinas, AS</a2>
  <t1>Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial</t1>
  <t2>Cancer med.</t2>
  <sn/>
  <op/>
  <vo/>
  <ab/>
  <la>eng</la>
  <k1/>
  <pb/>
  <pp/>
  <yr>2019</yr>
  <ed/>
  <ul>http://zaguan.unizar.es/record/86474/files/texto_completo.pdf;
	http://zaguan.unizar.es/record/86474/files/texto_completo.jpg?subformat=icon;
	</ul>
  <no>Imported from Invenio.</no>
</reference>

</references>